Celcuity

Celcuity is a commercial stage oncology company whose approved drug, REVTORPYK (gedatolisib), is a kinase inhibitor of the PI3K/AKT/mTOR (“PAM”) pathway.

Celcuity details its gedatolisib program, a next-generation targeted therapy for cancer.

View the FDA-approved medicines from Celcuity, a commercial-stage oncology company advancing next-generation targeted therapies for cancer.

Celcuity presents its drug pipeline for targeted therapies in breast cancer and other solid tumors.

View scientific posters from Celcuity, a commercial-stage oncology company advancing targeted therapies for breast cancer and other solid tumor indications.

Celcuity lists job opportunities in oncology therapy development for cancers involving the PAM (PI3K/AKT/mTOR) pathway.

Celcuity describes its company culture in oncology therapy development for cancers involving the PAM (PI3K/AKT/mTOR) pathway.

Celcuity’s leadership oversees a commercial-stage oncology company developing therapies for cancers involving the PAM (PI3K/AKT/mTOR) pathway.

Celcuity supports patient advocacy for targeted therapies in breast cancer and other solid tumor types.

Celcuity develops targeted therapies for cancers involving the PAM (PI3K/AKT/mTOR) pathway.

Based in Minneapolis, MN, Celcuity is a commercial-stage company advancing next-generation therapies for breast cancer and other solid tumors.

Celcuity is a commercial-stage company advancing targeted therapies for breast cancer and other solid tumors with PAM (PI3K/AKT/mTOR) pathway involvement.

Celcuity provides its California Compliance Declaration for targeted therapies in breast cancer and other solid tumors.

Celcuity outlines its terms of use for targeted therapies in breast cancer and other solid tumors.